Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Oncology Drugs - New Zealand

New Zealand
  • In New Zealand, the projected revenue in the Oncology Drugs market for 2024 is estimated to be US$245.50m.
  • This indicates a positive trajectory for the market.
  • Furthermore, it is anticipated that the market will experience an annual growth rate (CAGR 2024-2029) of 6.86%.
  • As a result, the market volume is predicted to reach US$342.00m by 2029.
  • This growth is significant and showcases the potential for expansion in the Oncology Drugs market.
  • When comparing globally, it is noteworthy that United States is expected to generate the highest revenue in the Oncology Drugs market.
  • In 2024, United States is projected to generate US$103.90bn, highlighting its dominance in the industry.
  • This indicates the strong market presence and economic strength of the United States in the field of Oncology Drugs market.
  • New Zealand's oncology drugs market is witnessing a surge in demand due to the country's aging population and increasing prevalence of cancer.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

In-Scope

  • Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
  • Chemotherapeutic agents
  • Immuno-oncology drugs
  • Oncology orphan drugs

Out-Of-Scope

  • Radiation therapy
  • Medical devices
Oncology Drugs: market data & analysis - Cover

Market Insights report

Oncology Drugs: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    New Zealand, a country famous for its natural beauty and adventure tourism, has been experiencing a steady growth in the oncology drugs market.

    Customer preferences:
    The demand for oncology drugs in New Zealand is driven primarily by an aging population and a growing incidence of cancer. Cancer is the leading cause of death in the country, and the number of new cancer diagnoses has been steadily increasing over the years. Patients in New Zealand prefer personalized treatment plans, which has led to an increase in the use of targeted therapies.

    Trends in the market:
    The oncology drugs market in New Zealand has been witnessing a shift from traditional chemotherapy to targeted therapies and immunotherapies. There has been a rise in the number of clinical trials for cancer drugs in the country, which has increased access to innovative therapies for patients. The government has also been taking steps to improve access to oncology drugs by funding new treatments and expanding the range of drugs available in the public healthcare system.

    Local special circumstances:
    New Zealand has a unique healthcare system that combines both public and private healthcare services. The government funds a significant portion of healthcare services, including cancer treatment. However, there is also a thriving private healthcare sector that offers more personalized treatment options. Additionally, the country's geographic location and small population size can make it challenging to access certain drugs or treatments, which can impact the availability and cost of oncology drugs.

    Underlying macroeconomic factors:
    New Zealand's economy has been growing steadily over the years, which has led to an increase in healthcare spending. The country has a high standard of living and a well-developed healthcare system, which has contributed to the growth of the oncology drugs market. Additionally, the government has been taking steps to improve access to healthcare services, including cancer treatment, which has further fueled the demand for oncology drugs. In conclusion, the growing incidence of cancer, an aging population, and a shift towards personalized treatment options have been driving the growth of the oncology drugs market in New Zealand. The government's focus on improving access to healthcare services and funding new treatments has also contributed to the growth of the market. However, the unique healthcare system and geographic location of the country can pose challenges in accessing certain drugs or treatments.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Oncology Drugs: market data & analysis - BackgroundOncology Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Cancer worldwide - Statistics & Facts

    Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.